Reluctance of the multinational pharmaceutical companies to join
the Medicines Patent Pool plan for HIV drugs (antiretrovirals-ARVs) might undermine its desirable objective of scaling up long-term, extended access to novel, afordable and appropriate ARV formulations in resource-limited...
Más información
